Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm Shire has said that Elaprase, a human enzyme replacement therapy for the treatment of Hunter syndrome, has been approved for commercial sale by the Mexican Federal Commission for Protection against Sanitary Risk or COFEPRIS.
Subscribe to our email newsletter
Sylvie Gregoire, president of Shire HGT, the Shire business unit focused on genetic diseases, said: “The approval of Elaprase in Mexico marks a significant milestone because for the first time, Hunter syndrome patients in Mexico have access to treatment.”